Are you or a loved one living with hemophilia B?

ATHN (American Thrombosis and Hemostasis Network) invites you to join an open-label research study of the long-term safety of nonacog beta pegol, N9-GP (brand name Rebinyn®), in adults and children with hemophilia B.

You can make a difference!

When you participate in this research study, you’re taking an important step to help researchers better understand the safety and effectiveness of nonacog beta pegol. Collecting and studying data on how you and other participants respond to treatment is essential to advancing science and ultimately improving care for everyone with hemophilia B.

The study is called ATHN Transcends: Coagulation Factor IX (Recombinant) GlycoPEGylated Module and is being conducted at treatment centers across the country. Nonacog beta pegol, N9-GP, is indicated for on-demand treatment and control of bleeding episodes, management of perioperative bleeding, and routine prophylaxis.

We care about confidentiality.

To participate in the study, you will need to:

  • Sign an informed consent form
  • Agree to be treated with nonacog beta pegol
  • Complete study activities
QR code to learn more about joining the research study

Thank you for helping us improve care! CLICK HERE or Scan this code for more information about joining the research study.